AI assistant
Abnova AGM Information 2026
52384_rns_2026-06-08_06f0133a-8bee-40e6-a370-86d7f3509c04.pdf
AGM Information
Open in viewerOpens in your device viewer
(This translated document is prepared in accordance with the Chinese version and is for reference only. In the event of any inconsistency between the English version and the Chinese version, the Chinese version shall prevail.)
Abnova (Taiwan) Corporation
Meeting Minutes of General Shareholders’ Meeting 2026
Type of Meeting: Physical shareholders’ meeting
Time: 9 a.m. on Friday, May 29, 2026
Place: 1F., No. 207, Sec. 2, Tiding Blvd., Neihu Dist., Taipei City, Taiwan (R.O.C.)
(XUE XUE Foundation Building)
Total outstanding shares of Abnova (Taiwan) Corporation: 60,553,594 shares
Total shares represented by shareholders present (including the shares with e-voting rights 2,423,344 shares): 34,613,885 shares
Percentage of shares held by shareholders present: 57.16%
Direct Present: Wilber Huang (Chairperson), Chiu Chi Ching (Representative of Harmony Investment Co., Ltd.), Jih Pei Ju (Representative of Pan Pacific Investment Corp.), Cha Anna (Convener of Audit Committee)
Attendees: Chang Ya Ping (Accounting Officer), Chiang Hsiao Ling (KPMG Certified Public Accountant)
Chairperson: Wilber Huang, the chairperson of Board of Directors
Secretary: Tung I Ling
-
Call the Meeting to Order:
The aggregate shareholding of the shareholders present constituted a quorum. The Chairperson called the meeting to order. -
Chairperson Remarks: (omitted)
-
Reported Matters
(1) 2025 Business Report (please refer to Appendix 1)
(2) Audit Committee’s Review Report on the 2025 Financial Statements (please refer to Appendix 2)
(3) Remuneration Distribution Report for Employees and Directors of 2025 (please refer to MEETING HANDBOOK Page 2)
(4) 2025 Remuneration report of directors (please refer to MEETING HANDBOOK Page 2~5)
(5) 2025 Profit Distribution Report (please refer to Appendix 4)
- 2 -
4. Matters for Ratification
No. 1
(Proposed by the Board)
Proposal: Adoption of 2025 Business Report and Financial Statements
Explanation:
1. 2025 Financial statements (including individual and consolidated statements) have been audited by KPMG Certified Public Accountants, Chiang Hsiao Ling and Wu Tsao Jen, and issued an audit report, which has been reviewed by the Audit Committee.
2. 2025 Business Report, 2025 Inspection Report of Audit Committee, 2025 Annual Financial Statements and CPA's Audit Report, please refer to Appendix 1-3.
3. Please adopt.
Resolution:
The proposal was approved by the votes of shareholders present. The voting results are as follows.
Shares represented at the time of voting: 34,613,885
| Voting Results | % of the total represented share present |
|---|---|
| Votes in favor: 33,468,121 votes | |
| (including 1,277,580 votes casted electronically) | 96.68% |
| Votes against: 93,263 votes | |
| (including 93,263 votes casted electronically) | 0.26% |
| Votes invalid: 0 vote | 0.00% |
| Votes abstained: 1,052,501 votes | |
| (including 1,052,501 votes casted electronically) | 3.04% |
※The percentage of shareholders' voting rights is unconditionally rounded to the second decimal place, which may result in a fractional difference, resulting in the total number of percentages not equal to 100%.
No.2
(Proposed by the Board)
Proposal: Adoption of 2025 Profit Distribution
Explanation:
1. The accumulated unappropriated retained earnings are NTD 65,760,459, deducted the net loss after tax in 2025 is NTD 1,141,279 and added NTD 223,096 earnings due to remeasurements of the net defined benefit plan and reversal of NTD 2,511,476 special reserve, the distributable net profit is NTD 67,353,752. The proposed dividend to shareholders is NTD 6,782,003. The distribution of shareholder dividends is planned to be distributed preferentially from the 2025 profit. To learn more about the 2025 Profit distribution statement, please refer to Appendix 4.
2. This cash dividend will be calculated based on the shareholding ratio recorded in the shareholder register on the ex-dividend base date (rounded down to the nearest dollar).
The total amount of odd lots (less than one full share) will be purchased by people designated by the chairperson as authorized by the board of directors.
-
After the proposal is approved by the shareholders' regular meeting, the chairperson is authorized to determine the ex-dividend base date and other relevant matters.
-
If, before the distribution record date, the proposed profit distribution is affected by a buyback of shares or issuance of new shares for transferring treasury shares, cancellation or capital reduction, etc. causing changes in the number of outstanding shares, it is proposed that the chairperson be authorized to adjust the cash to be distributed to each share.
-
Please adopt.
Resolution:
The proposal was approved by the votes of shareholders present. The voting results are as follows.
Shares represented at the time of voting: 34,613,885
| Voting Results* | % of the total represented share present |
|---|---|
| Votes in favor: 33,465,856 votes | |
| (including 1,275,315 votes casted electronically) | 96.68% |
| Votes against: 96,263 votes | |
| (including 96,263 votes casted electronically) | 0.27% |
| Votes invalid: 0 vote | 0.00% |
| Votes abstained: 1,051,766 votes | |
| (including 1,051,766 votes casted electronically) | 3.03% |
※The percentage of shareholders' voting rights is unconditionally rounded to the second decimal place, which may result in a fractional difference, resulting in the total number of percentages not equal to 100%.
- Matters for Discussion
No.1
(Proposed by the Board)
Proposal: Revision of "Procedures for Acquisition or Disposal of Assets"
Explanation:
-
Pursuant to 24 July 2025 Directive FSC-Issuance-Zi-No. 1140383333 of the Financial Supervisory Commission (FSC), partial provisions of the Company's "Procedures for Acquisition or Disposal of Assets" has been amended by addition of matters concerning. For the comparison table of the Company's "Procedures for Acquisition or Disposal of Assets" before and after amendment, please refer to Appendix 5.
-
For your discussion.
Resolution:
The proposal was approved by the votes of shareholders present. The voting results are as follows.
Shares represented at the time of voting: 34,613,885
| Voting Results* | % of the total represented share present |
|---|---|
| Votes in favor: 33,464,411 votes (including 1,273,870 votes casted electronically) | 96.67% |
| Votes against: 94,640 votes (including 94,640 votes casted electronically) | 0.27% |
| Votes invalid: 0 vote | 0.00% |
| Votes abstained: 1,054,834 votes (including 1,054,834 votes casted electronically) | 3.04% |
※The percentage of shareholders' voting rights is unconditionally rounded to the second decimal place, which may result in a fractional difference, resulting in the total number of percentages not equal to 100%.
6. Elections Matters
No.1
(Proposed by the Board)
Proposal: Re-election of all directors
Explanation:
- The term of all directors of the 9th Board of Directors will end on May 14, 2026. According to article 17 of Articles of Incorporation and article 195 of Company Act, the company proposes to duly elect new Board members at this year's General Meeting of Shareholders.
- The shareholders' meeting shall elect 7 directors (including 3 independent directors). For the 10th Board of Directors, their three-year term will start from May 29, 2026, and conclude on May 28, 2029. The directors (including independent directors) shall be elected from the nomination list prepared by the company. The term of the 9th Board of Directors will end at the completion of this regular meeting of shareholders.
- The related personal information such as education and experience of the nominees is as follows:
List of candidates for directors:
| No | Account Number | Name of Candidate | Shareholding | Main education, experience, and current position |
|---|---|---|---|---|
| 1 | 115 | Wilber Huang | 3,651,144 | Education: M.D, Northwestern University Medical School Experience/ Current Position: 1. Chairperson of Abnova (Taiwan) Corporation 2. Chairperson of Abnova Holding Corporation 3. Chairperson of Citil Pharma Incorporated 4. Chairperson of AxleBio Ventures 5. Chairperson of Abnova USA Inc. |
| 2 | 30 | Harmony Investment Co., Ltd. | 2,448,294 | Education: Bachelor’s degree in Housing and Architecture, Japan Women's University |
- 5 -
| No | Account Number | Name of Candidate | Shareholding | Main education, experience, and current position |
|---|---|---|---|---|
| Representative: Chiu Chi Ching | Experience / Current Position: 1. Chairperson of Harmony Investment Co., Ltd. 2. Chairperson of Lasertech Holding International Ltd. 3. Chairperson of Attebury Investments International Ltd. 4. Supervisor of Pan Pacific Investment Corp. 5. Chairperson of Bolster Pioneering Incorporated | |||
| 3 | 56 | Pan Pacific Investment Corp. Representative: Jih Pei Ju | 1,839,014 | Education: Master's degree in Institute of Plant Biology, National Taiwan University Experience / Current Position: President of Abnova (Taiwan) Corporation |
| 4 | 123 | China Wire & Cable Co., Ltd Representative: Chen Yueh Hung | 1,037,017 | Education: Bachelor's degree, University of Toronto Experience / Current Position: 1. Chairperson of Kai Tse Co., Ltd. 2. Director of Great Universe Metal Building Materials Corp. 3. Director of Great Universe Enterprises Co., Ltd. 4. Director of Taiwan Sun Clutch Co., Ltd. 5. Supervisor of Great Universe Development Corp. 6. Deputy Chairperson of LiBAiDAi Construction & Development Co., Ltd. 7. Director of Tai Hsu Construction & Development Co., Ltd. 8. Director of Yi De Xin Construction & Development Co., Ltd. 9. Director of Hung Kuan Ltd. |
List of candidates for independent directors:
| No | Account Number | Name of Candidate | Shareholding | Main education, experience, and current position | Served three consecutive terms as Independent director |
|---|---|---|---|---|---|
| 1 | — | Cha Anna | 0 | Education: Bachelor's degree in dance, Chinese Culture University Experience / Current Position: 1. Chairperson of Rouge Creative Marketing Co. 2. Chairperson of Chipcom International Co., Ltd. | None |
| 2 | — | Tsai Huey Cherng | 0 | Education: Ph.D, Department of Business Management, National Sun Yat Sen University Experience / Current Position: 1. Assistant Professor, Department of Finance, STUST. 2. Director of Accounting Office, STUST. 3. Independent Director of Ton Yi Industrial Corp. | None |
| 3 | — | Hsu Chih Kai | 0 | Education: Bachelor's degree in architecture, Tunghai University Experience / Current Position: 1. Architect of K-Architect 2. Chairman of K-Design Co., Ltd. 3. Chairman of K-Development | None |
- Please proceed to vote.
Voting Results:
The list of 10th directors and independent directors of the Company elected are as follows:
| Title | Account or ID No. | Name | Votes |
|---|---|---|---|
| Director | 115 | Wilber Huang | 42,506,525 votes |
| Director | 30 | Harmony Investment Co., Ltd. | |
| Representative: Chiu Chi Ching | 34,809,052 votes | ||
| Director | 56 | Pan Pacific Investment Corp. | |
| Representative: Jih Pei Ju | 33,497,731 votes | ||
| Director | 123 | China Wire & Cable Co., Ltd. | |
| Representative: Chen Yueh Hung | 32,125,151 votes | ||
| Independent director | J2203XXXXX | Cha Anna | 30,616,706 votes |
| Independent director | S1213XXXXX | Tsai Huey Cherng | 29,588,904 votes |
| Independent director | A1250XXXXX | Hsu Chih Kai | 28,391,743 votes |
- Other Matters
No.1
(Proposed by the Board)
Proposal: Proposal of Release the Prohibition on New Directors from Participation in Competitive Business
Explanation:
- According to article 209 of Company Act, A director who does anything for himself or on behalf of another person that is within the scope of the company's business, shall explain to the meeting of shareholders the essential contents of such an act and secure its approval.
- On the premise of not damaging the interests of the company, if the newly elected directors and their representatives of the Company invest in other companies with the same or similar business scope as the Company, the proposal of releasing the Prohibition on New Directors from Participation in Competitive Business will be submitted to the shareholders' meeting for approval.
- The details of the concurrent positions of the 10th directors elected at the general shareholders meeting are as follows.
The list of Release the Prohibition on 10th New Directors and the Representatives from Participation in Competitive Business :
| Title | Name | Concurrent positions in other companies |
|---|---|---|
| Director | Wilber Huang | 1. Chairperson of Abnova Holding Corporation |
| 2. Chairperson of Citil Pharma Incorporated | ||
| 3. Chairperson of AxleBio Ventures | ||
| 4. Chairperson of Abnova USA Inc. | ||
| Director | Harmony Investment Co., Ltd. | |
| Representative: Chiu Chi Ching, | 1. Chairperson of Harmony Investment Co., Ltd. | |
| 2. Chairperson of Lasertech Holding International Ltd. | ||
| 3. Chairperson of Attebury Investments International Ltd. | ||
| 4. Supervisor of Pan Pacific Investment Corp. | ||
| 5. Chairperson of Bolster Pioneering Incorporated | ||
| Director | Pan Pacific Investment Corp. | |
| Representative: Jih Pei Ju | None | |
| Director | China Wire & Cable Co., Ltd | |
| Representative: | 1. Chairperson of Kai Tse Co., Ltd. | |
| 2. Director of Great Universe Metal Building Materials Corp. |
| Title | Name | Concurrent positions in other companies |
|---|---|---|
| Chen Yueh Hung | 3. Director of Great Universe Enterprises Co., Ltd. | |
| 4. Director of Taiwan Sun Clutch Co., Ltd. | ||
| 5. Supervisor of Great Universe Development Corp. | ||
| 6. Deputy Chairperson of LiBAiDAi Construction & Development Co., Ltd. | ||
| 7. Director of Tai Hsu Construction & Development Co., Ltd. | ||
| 8. Director of Yi De Xin Construction & Development Co., Ltd. | ||
| 9. Director of Hung Kuan Ltd. | ||
| Independent Director | Cha Anna | 1. Chairperson of Rouge Creative Marketing Co. |
| 2. Chairperson of Chipcom International Co., Ltd. | ||
| Independent Director | Tsai Huey Cherng | 1. Assistant Professor, Department of Finance, STUST. |
| 2. Director of Accounting Office, STUST. | ||
| 3. Independent Director of Toon Yi Industrial Corp. | ||
| Independent Director | Hsu Chih Kai | 1. Architect of K-Architect |
| 2. Chairperson of K-Design Co., Ltd. | ||
| 3. Chairperson of K-Development |
- Please proceed to discuss.
Resolution:
The proposal was approved by the votes of shareholders present. The voting results are as follows.
Shares represented at the time of voting: 34,613,885
| Voting Results* | % of the total represented share present |
|---|---|
| Votes in favor: 33,112,658 votes | |
| (including 922,117 votes casted electronically) | 95.66% |
| Votes against: 378,067 votes | |
| (including 378,067 votes casted electronically) | 1.09% |
| Votes invalid: 0 vote | 0.00% |
| Votes abstained: 1,123,160 votes | |
| (including 1,123,160 votes casted electronically) | 3.24% |
※The percentage of shareholders' voting rights is unconditionally rounded to the second decimal place, which may result in a fractional difference, resulting in the total number of percentages not equal to 100%.
-
Questions and Motions: None
-
There was no question raised by shareholders at the shareholders' meeting regarding the Reported Matters, Matters for Ratification, Matters for Discussion, Elections Matters, Other Matters and Questions and Motions.
-
Adjournment
On Friday, May 29, 2026, the Chairperson declared the meeting adjourned at 9:30 a.m.
*The meeting minutes only specify the gist of the meeting, and the contents and procedures of the meeting are subject to the audio and video of the meeting.
Appendix 1
Abnova (Taiwan) Corporation
2025 Business Report
Appreciate the shareholders’ support of Abnova. The following is Abnova's 2025 achievement sharing and 2026 outlook report:
I. 2025 Operating Results: (Consolidated Financial Statements)
-
Implementation overview and business plan implementation results:
The operating revenue in 2025 was NTD 351,299 thousand, which is 1.11% lower than the 2024 operating income of NTD 355,257 thousand. The net loss after tax in 2025 was NTD 1,141 thousand, which is a decrease of 101.85% compared with the net profit after tax of NTD 61,607 thousand in 2024. The loss per share for 2025 was NTD 0.02. -
Analysis of financial balance and profitability: Please refer to the attached financial statements for the financial overview of 2025.
-
Research Development Overview: The expenses invested in research and development in 2025 were NTD 45,561 thousand, which is 13.83% higher than the 2024 expenses of NTD 45,561 thousand. The company’s R&D efforts primarily focused on mRNA-related applications, In Vivo Grade Functional Antibodies, and RNAutomation™ mRNA Upgrades Systems etc.
II. 2026 Business Plan:
- Business Marketing:
Since 2025, Abnova has been collaborating with the academic literature AI search engine CiteAb to integrate the AI Citation Widget into its official website. Using advanced AI, extensive citation data are introduced to present product-related academic citation information in real time. In 2026, the Company will continue to deepen this collaboration by deploying a second-generation, SEO-optimized AI Citation Widget to enhance the visibility of Abnova’s products in Google Scholar search results.
Meanwhile, Abnova continues to optimize its website search functionality. In response to researchers’ use of habits for integrated search, a new application-oriented search mechanism has been introduced, allowing users to simultaneously search by product name and application area, thereby improving both search efficiency and precision.
Regarding digital marketing strategy, Abnova uses LinkedIn advertising to promote new products and key product lines, effectively reaching the global scientific research community. As of November 2025, the number of e-newsletter subscribers has grown to 560,000. Through monthly, theme-based technical content—covering product technology profiles and explanations of new applications—Abnova continues to reinforce researchers’ trust in its professional capabilities and enhance brand awareness.
Looking ahead to 2026, Abnova will take digitalization and intelligentization as its core development directions, further deepening the application of AI technologies and content
- 8 -
marketing strategies, integrating three key dimensions: academic citation, search experience, and brand promotion, to build a more efficient and precision-oriented scientific research service platform, while continuously strengthening its professional influence in the global research market.
2. Product Development:
(1) RNA Laboratory Reagents
Abnova's RNA laboratory reagents are categorized into six major groups based on RNA molecular types and biological characteristics, including mRNA, circRNA, dsRNA, miRNA, lncRNA, and Total RNA. These reagents comprehensively cover research applications across different RNA types and support diverse experimental needs, from basic research to preclinical studies.
- mRNA products: Provide capping reagents, reaction enzymes, nucleotides, and products related to mRNA synthesis and purification, widely applied in gene expression studies and mRNA vaccine development.
- circRNA products: Focus on synthesis and labeling-related technologies, enabling researchers to investigate the molecular stability, biological functions, and potential applications of circRNA in depth.
- dsRNA products: Primarily used for double-stranded RNA research, supporting RNA interference mechanisms and innate immune response analysis. The products include dsRNA antibodies and test kits suitable for functional studies at both cellular and molecular levels.
- miRNA products: Offer comprehensive solutions including probes, PCR reagents, and purification tools for the detection, quantification, and analysis of gene regulatory mechanisms of miRNA.
- lncRNA products: For research applications, they are currently focused on PCR-related reagents to support expression analysis and functional studies of long non-coding RNAs.
- Total RNA products: Provide a complete set of reagents and tools from RNA extraction and purification to downstream analysis, enabling researchers to establish stable and high-quality RNA experiment workflows.
Abnova's RNA laboratory reagents comprehensively support a wide range of RNA research, providing researchers with essential reagents and tools at various stages of their work and consistently meeting the professional needs of both basic research and preclinical applications.
- RNA Laboratory Reagents:
www.abnova.com/en-global/product?category=BE0000000000
图
(2) In Vivo Functional Grade Antibodies
Abnova's in vivo functional grade antibodies are specifically designed for in vivo studies in mice and rats. These antibodies are characterized by high purity, ultra-low endotoxin levels, and are free from preservatives and stabilizers, effectively minimizing non-specific immune interference and ensuring the safety of animal studies and the reliability of data. All antibodies are validated by flow cytometry, with functionality confirmed through comparisons between positive and negative cell lines, ensuring consistent quality and experimental rigor.
These products cover two major categories:
- Antibodies targeting mouse genes: Suitable for studies involving implantation of mouse tumor cells into immunocompetent mice, enabling the simulation of target gene functions and effects within the mouse immune system.
- Antibodies targeting human genes: Suitable for models involving implantation of human tumor cells into immunodeficient mice, simulating the targeting effects and regulatory mechanisms of antibodies against human tumors.
These two systems are designed to address different tumor origins and immune backgrounds, providing a more comprehensive evaluation of in vivo functionality and helping researchers thoroughly validate the biological activity of antibody targets. In vivo functional grade antibodies have become essential tools in tumor immunology, immune regulation, and disease model research. They not only enable precise simulation of physiological mechanisms but also effectively support the validation of antibodies' therapeutic potential, thereby accelerating drug development and the translational research process.
- In Vivo Functional Grade Antibodies Product Catalogue:
www.abnova.com/en-global/product/specializedproductsearch/invivomab
(3) VLP and Nanodisc Membrane Protein Expression Systems:
Membrane proteins are critical targets for many drugs. However, due to their highly complex transmembrane structures, challenges such as structural instability, loss of activity, and improper membrane insertion during expression and purification have long limited their functionality, making membrane protein research and drug development a persistent bottleneck.
Abnova integrates two core technology platforms—VLP (Virus-Like Particle) and Nanodisc—to overcome the limitations of conventional preparation techniques,
enabling stable expression while preserving the structural integrity and functional activity of membrane proteins:
- VLP platform: Composed of virus-like shells, this platform can stably encapsulate membrane proteins and simulate the native membrane environment. It does not contain viral genomes and can ensure a high level of safety.
- Nanodisc platform: Provides a membrane environment similar to that of natural cell membranes, allowing membrane proteins to maintain correct structure and activity. Without the need for surfactants, membrane proteins can be stably dissolved in aqueous solutions, facilitating follow-up analysis and drug screening.
Through multiple validations of biological activity and structural integrity, Abnova has demonstrated that membrane proteins prepared by these two platforms exhibit high stability and reproducible functionality. This technology not only overcomes key challenges in membrane protein preparation but also establishes a scalable, reproducible, and industry-ready technical foundation for basic research, drug discovery, and clinical applications.
- VLP and Nanodisc Membrane Protein Product Catalogue
www.abnova.com/en-global/product/specializedproductsearch/vlpnanodisc
(4) circRNA Sponge
circRNA Sponge is an artificial circular non-coding RNA that integrates multiple miRNA-targeting sequences, thereby enhancing the diversity of adsorption. Compared with linear RNA sponges, circRNA Sponge lacks 5' and 3' ends, exhibits low immunogenicity without the need for nucleoside modification, and is resistant to exonuclease degradation, thereby improving adsorption stability and efficiency. circRNA Sponge also overcomes the toxicity concerns associated with traditional anti-miRNA oligonucleotides (AMOs) and the dose limitations of plasmid-based circRNA Sponge. Abnova has successfully overcome challenges related to production capacity and purity, and has validated the biological activity of circRNA Sponge in cell-based in vivo assays. This stable and highly efficient circRNA Sponge product line supports miRNA research in both in vitro and in vivo settings.
- circRNA Sponge Service :
www.abnova.com/en-global/services/circrna_sponges
(5) RNAutomation™ mRNA Upgrades :
With the rapid emergence of mRNA vaccines and RNA therapeutics, the demand for RNA in vitro transcription (IVT) technologies continues to grow. However, conventional manual workflows are prone to RNA degradation, batch-to-batch variability, and operator-induced errors, which reduce reproducibility and significantly increase development costs and time pressure. To meet the need for high efficiency, stability, and reproducibility, automation techniques have become a key driver in advancing RNA research and application development.
Since 2019, Abnova has been dedicated to developing RNA IVT platforms. Building on its long accumulated capacity in RNA cancer vaccine development, Abnova has launched the world's first integrated RNA automated production platform—RNAutomation™ mRNA Upgrades System. With Opentrons Flex™ as its core, the system integrates pre-validated software, reagents, and consumables from Abnova, enabling automated execution of IVT, capping, oligo(dT) purification, and cellulose purification processes. It stably produces mRNA with high uniformity and reproducibility, suitable for pharmacological evaluation, dose optimization, and preclinical research.
Regarding the hardware configuration of RNAutomation™ mRNA Upgrades System, in addition to the standard Opentrons Flex™ components—including thermal cyclers, temperature modules, heater-shaker modules, magnetic modules, and high-precision liquid-handling modules—it also introduces Abnova's self-developed vacuum suction module. This module enables the purification process of cellulose to effectively remove double-stranded RNA (dsRNA) impurities commonly seen during mRNA production, thereby improving mRNA purity and quality.
Through default automated software procedures combined with pre-validated reagents and consumables, the system enables the automatic completion of IVT, capping, oligo(dT), and cellulose purification processes. Abnova also provides customized process software development and validation services to meet diverse customer requirements in process design and production scale.
For research institutions that have already deployed the Opentrons Flex™ system, a complete mRNA automated production workflow can be rapidly established by adopting Abnova's pre-validated software and self-developed vacuum suction module solely, thereby significantly lowering the barrier to system deployment.
The launch of the RNAutomation™ mRNA Upgrades System enables researchers to rapidly enter the field of RNA research and development. Its applications include pharmacological and dose optimization, preclinical GLP studies, and toxicological evaluation. It is broadly applicable across various research and development areas, including next-generation RNA vaccines, biologics, immunotherapies, and cell and gene therapy.
- 12 -
This platform not only demonstrates Abnova's innovation in RNA automated manufacturing technologies but also further establishes its professional leadership in platform-based RNA research and development.
- RNAutomation™ mRNA Upgrades System :
www.abnova.com/en-global/systems-automations/detail/m0028
- RNAutomation™ Service :
www.abnova.com/en-global/services/rnautomation_service
- RNAutomation™ Videos :
www.abnova.com/en-global/support/abvideo/system/content/rnautomation_mrna_service_video
III. The effect of external competition, the legal environment, and the overall business environment
1. External Competition:
In recent years, the health of humankind and the global economy has been impacted by the outbreak of various infectious diseases, leading to increasing attention to the biotechnology and medicine industry.
Various countries have introduced incentive policies, which will attract many competitors to join, but also promote the vigorous development of the biotechnology and medical industry, cultivating more outstanding talents, which is expected to contribute to the long-term development of the whole industry.
2. Legal Environment:
Abnova strictly controls product quality and has ISO9001 certification of Neihu Plant. In response to the needs of different products and countries, relevant laws and regulations of various countries shall be followed. Meeting the above specifications will increase the management and application costs, but at the same time, it can also guarantee product quality and improve customer recognition.
- Overall Business Environment:
About 97% of Abnova's products are exported, and the main sales areas are America, Europe, Japan, etc. The transaction currency is mainly USD, followed by Euro. Since the recent uncertainty in the international political and economic situation, fluctuations in the US dollar exchange rate have had an impact on the Company, the financial department closely observes the exchange rate trend and timely assesses whether to conduct hedging derivative financial transactions to reduce the exchange rate risk.
In 2026, Abnova will adhere to the original intention of professionalism, focus, and quality, and continue to push itself for deeper technological innovation. Looking forward to the future, it may face variable operational opportunities and challenges. Abnova will continue to strengthen its competitive strength and accumulate more growth momentum to create better operating results.
Chairperson: Wilber Huang
General Manager: Jih Pei Ju
Accounting Officer: Chang Ya Ping
- 14 -
Appendix 2
Abnova (Taiwan) Corporation
Audit Committee’s Review Report on the 2025 Financial Statements
The Board of Directors prepared the Company's business report, financial statements, and profit distribution proposal for 2025. The financial statements have been audited by KPMG accounting firm and an audit report has been issued. The above business report, financial statements, and profit distribution proposal have been audited by the Audit Committee and there is no nonconformity, so the feedback is reported as above in accordance with the relevant provisions of the Securities and Exchange Act and the Company Act, please proceed to the certificate.
Abnova (Taiwan) Corporation
Convener of Audit Committee: Cha Anna
February 25, 2026
- 15 -
Appendix 3
Independent Auditors’ Report
To the Board of Directors of Abnova (Taiwan) Corporation:
Opinion
We have audited the consolidated financial statements of Abnova (Taiwan) Corporation and its subsidiaries (“the Group”), which comprise the consolidated balance sheets as of December 31, 2025 and 2024, the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.
In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of Abnova (Taiwan) Corporation and its subsidiaries as of December 31, 2025 and 2024, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and with the International Financial Reporting Standards (“IFRSs”), International Accounting Standards (“IASs”), Interpretations developed by the International Financial Reporting Interpretations Committee (“IFRIC”) or the former Standing Interpretations Committee (“SIC”) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.
Basis for opinion
We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and auditing standards. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Consolidated Financial Statement section of our report. We are independent of the Group in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Key audit matter
Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The key audit matters we judge that shall be communicated in the audit report are as follows:
1. Inventory valuation
Please refer to Note 4(8) “Inventories”; Note 5(1) “Significant accounting assumptions and judgments, and major sources of estimation uncertainty”, and Note 6(4) “Inventories”.
Description of key audit matter:
The major business of Abnova (Taiwan) Corporation is the manufacturing and sales of antibody, protein, test reagents and testing instruments. Inventories are measured at the lower of cost and net realizable value. Due to the longer life cycle of the products, the management considers factors such as product circulation, exposure, preservation and industry information to evaluate the net realizable value of inventories. As Abnova (Taiwan) Corporation has large amount of inventories and a large number of items, and the net realizable value used in the above-mentioned evaluation involves subjective judgment, the evaluation of loss allowance for inventory valuation has been listed as the key audit matter of the year.
- 16 -
Our principal audit procedures included:
The key audit procedures for the above-mentioned key audit matter based on the understanding of the industrial characteristics of Abnova (Taiwan) Corporation include obtaining statistical information on the sales time and sales status of the products on the shelves in each year provided by the management in the subsequent years to evaluate the rationality of the policy used to recognize the inventory valuation loss; understanding Abnova (Taiwan) Corporation’s inventory management process, reviewing the annual inventory plan and participating in the annual inventory check to evaluate the effectiveness of the management’s inventory control; obtaining the inventory net realizable value calculation sheet, and spot check the correctness of the calculation.
Other matter
Abnova (Taiwan) Corporation has prepared its parent-company-only financial statements as of and for the years ended December 31, 2025 and 2024, on which we have issued an unqualified opinion.
Responsibilities of management and those charged with governance for the financial statements
Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and with the IFRSs, IASs, IFRC, SIC endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the consolidated financial statements, management is responsible for assessing the Group’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
Those charged with governance (including the Audit Committee) are responsible for overseeing the Group’s financial reporting process.
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.
As part of an audit in accordance with auditing standards, we exercise professional judgment and professional skepticism throughout the audit. We also:
A. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 17 -
B. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group’s internal control.
C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
D. Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Group’s to cease to continue as a going concern.
E. Evaluate the overall presentation, structure and content of the consolidated financial reports, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
F. Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.
KPMG
Auditors :
Securities : Financial-Supervisory-Securitie
Competents-Auditing-1080303300
Authority Financial-Supervisory-Securitie
Approved-certified No.
February 25, 2026
Abnova (Taiwan) Corporation and Subsidiaries
Consolidated Balance Sheets
December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| Assets | December 31, 2025 | December 31, 2024 | December 31, 2025 | December 31, 2024 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amount | % | Amount | % | Liabilities and equity | Amount | % | Amount | % | |||
| Current assets: | Current liabilities: | ||||||||||
| 1100 | Cash and cash equivalents (Note 6(1)) | $ 377,832 | 28 | 448,545 | 32 | 2130 | Contract liability-current (Note 6(14)) | $ 2,585 | - | 2,483 | - |
| 1170 | Accounts receivable, net (Note 6(3) and 7) | 50,305 | 4 | 43,066 | 3 | 2170 | Accounts payable | 14,400 | 1 | 18,982 | 1 |
| 1200 | Other receivables | 2,384 | - | 3,116 | - | 2200 | Other payables | 25,892 | 2 | 32,300 | 2 |
| 1220 | Current tax assets (Note 6(11)) | 6,388 | 1 | 3,687 | 1 | 2280 | Current lease liabilities (Note 6(9)) | 5,212 | - | 5,508 | 1 |
| 130X | Inventories (Note 6(4)) | 468,874 | 35 | 451,886 | 32 | 2300 | Other current liabilities | 5,698 | 1 | 5,444 | - |
| 1479 | Other current assets (Note 8) | 9,675 | 1 | 16,940 | 1 | Total current liabilities | 53,787 | 4 | 64,717 | 4 | |
| Total current assets | 915,458 | 69 | 967,240 | 69 | Non-current liabilities: | ||||||
| Non-current assets: | 2570 | Deferred tax liabilities (Note 6(11)) | 2,942 | - | 8,006 | 1 | |||||
| 1517 | Non-current financial assets measured at fair value through other comprehensive income (Note 6(2)) | - | - | - | - | 2580 | Non-current lease liabilities (Note 6(9)) | 13,287 | 1 | 18,498 | 1 |
| 2600 | Other non-current liabilities (Note 6(5) and 7) | 724 | - | 427 | - | ||||||
| 1550 | Investments accounted for using equity method (Note 6(5)) | - | - | 64 | - | Total non-current liabilities | 16,953 | 1 | 26,931 | 2 | |
| 1600 | Property, plant and equipment (Note 6(6)) | 242,235 | 18 | 252,207 | 18 | Total liabilities | 70,740 | 5 | 91,648 | 6 | |
| 1755 | Right-of-use assets (Note 6(7)) | 18,278 | 1 | 23,936 | 2 | ||||||
| 1780 | Intangible assets (Note 6(8)) | 59,580 | 5 | 62,687 | 4 | Equity attributable to owners of parent (Note 6(12)) : | |||||
| 1840 | Deferred tax assets (Note 6(11)) | 87,684 | 7 | 91,258 | 7 | 3110 | Ordinary share | 605,536 | 45 | 605,536 | 43 |
| 1900 | Other non-current assets (Note 6(10) and 8) | 4,000 | - | 3,656 | - | 3200 | Capital surplus | 474,527 | 36 | 474,527 | 34 |
| Total non-current assets | 411,777 | 31 | 433,808 | 31 | Retained earnings: | ||||||
| 3310 | Legal reserve | 109,078 | 8 | 102,871 | 8 | ||||||
| 3320 | Unappropriated retained earnings | 7,592 | 1 | 12,199 | 1 | ||||||
| 3350 | Special reserve | 64,843 | 5 | 121,859 | 9 | ||||||
| 3400 | Other equity interest | (5,081) | - | (7,592) | (1) | ||||||
| Total equity | 1,256,495 | 95 | 1,309,400 | 94 | |||||||
| Total assets | $ 1,327,235 | 100 | 1,401,048 | 100 | Total liabilities and equity | $ 1,327,235 | 100 | 1,401,048 | 100 |
Chairman: WILBER HUANG
(See accompanying notes to financial statements.)
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Abnova (Taiwan) Corporation and Subsidiaries
Consolidated Statements of Comprehensive Income
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| 2025 | 2024 | ||||
|---|---|---|---|---|---|
| Amount | % | Amount | % | ||
| 4000 | Operating revenue (Note 6(14) and 7) | $ 351,299 | 100 | 355,257 | 100 |
| 5000 | Operating costs (Note 6(4)) | (195,488) | (56) | (191,998) | (54) |
| 5900 | Net gross profit | 155,811 | 44 | 163,259 | 46 |
| Operating expenses: | |||||
| 6100 | Marketing expenses | (47,828) | (13) | (42,220) | (12) |
| 6200 | Administrative expenses | (44,953) | (13) | (47,431) | (13) |
| 6300 | R&D expenses | (45,561) | (13) | (40,025) | (11) |
| 6450 | Gains on reversal of expected credit (loss) (Note 6(3)) | (418) | - | 687 | - |
| Total operating expenses | (138,760) | (39) | (128,989) | (36) | |
| 6900 | Net operating income | 17,051 | 5 | 34,270 | 10 |
| Non-operating income and expenses (Note 6(16)) : | |||||
| 7100 | Interest income | 10,757 | 3 | 17,315 | 5 |
| 7010 | Other income | 19 | - | 44 | - |
| 7020 | Other gains and losses | (28,889) | (8) | 21,883 | 6 |
| 7050 | Finance cost | (424) | - | (118) | - |
| 7060 | Share of associates and joint ventures income accounted for using equity method (Note 6(5)) | (543) | - | (205) | - |
| Total non-operating income and expenses | (19,080) | (5) | 38,919 | 11 | |
| 7900 | Profit (loss) from continuing operations before tax | (2,029) | - | 73,189 | 21 |
| 7950 | Tax expense (benefit) (Note 6(11)) | (888) | - | 11,582 | 3 |
| 8200 | Profit (loss) | (1,141) | - | 61,607 | 18 |
| Other comprehensive income: | |||||
| 8310 | Components of other comprehensive income that will not be reclassified to profit or loss | ||||
| 8311 | Remeasurements of defined benefit plans (Note 6(10)) | 223 | - | 465 | - |
| 8349 | Less: Income tax related to components of other comprehensive income that will not be reclassified to profit or loss | - | - | - | - |
| Components of other comprehensive income that will not be reclassified to profit or loss | 223 | - | 465 | - | |
| 8360 | Components of other comprehensive income (loss) that may be reclassified to profit or loss | ||||
| 8361 | Exchange differences on translation of foreign financial statements (Note 6(12)) | 2,511 | 1 | 4,607 | 1 |
| 8399 | Less: Income tax related to components of other comprehensive income that may be reclassified to profit or loss | - | - | - | - |
| Components of other comprehensive income (loss) that may be reclassified to profit or loss | 2,511 | 1 | 4,607 | 1 | |
| 8300 | Other comprehensive income, net of tax | 2,734 | 1 | 5,072 | 1 |
| 8500 | Total comprehensive income | $ 1,593 | 1 | 66,679 | 19 |
| Earnings (losses) per share (NT dollars) (Note 6(13)) | |||||
| 9750 | Basic earnings (losses) per share (NT dollars) | $ | (0.02) | 1.02 | |
| 9850 | Diluted earnings (losses) per share (NT dollars) | $ | (0.02) | 1.02 |
(See accompanying notes to financial statements.)
Chairman: WILBER HUANG
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Abnova (Taiwan) Corporation and Subsidiaries
Consolidated Statements of Changes in Equity
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| Equity attributable to owners of parent | ||||||||
|---|---|---|---|---|---|---|---|---|
| Retained earnings | Other equity interest | |||||||
| Ordinary shares | Capital surplus | Legal reserve | Special reserve | Unappropriated retained earnings | Exchange differences on translation of foreign financial statements | Unrealized gains (losses) from financial assets | ||
| measured at fair value through other comprehensive income | Total equity | |||||||
| Balance at January 1, 2024 | $ 605,536 | 474,527 | 98,565 | 11,907 | 107,983 | (7,254) | (4,945) | 1,286,319 |
| Profit | - | - | - | - | 61,607 | - | - | 61,607 |
| Other comprehensive income | - | - | - | - | 465 | 4,607 | - | 5,072 |
| Total comprehensive income | - | - | - | - | 62,072 | 4,607 | - | 66,679 |
| Appropriation and distribution of retained earnings: | ||||||||
| Legal reserve | - | - | 4,306 | - | (4,306) | - | - | - |
| Special reserve | - | - | - | 292 | (292) | - | - | - |
| Cash dividends on ordinary shares | - | - | - | - | (43,598) | - | - | (43,598) |
| Balance at December 31, 2024 | 605,536 | 474,527 | 102,871 | 12,199 | 121,859 | (2,647) | (4,945) | 1,309,400 |
| Loss | - | - | - | - | (1,141) | - | - | (1,141) |
| Other comprehensive income | - | - | - | - | 223 | 2,511 | - | 2,734 |
| Total comprehensive income | - | - | - | - | (918) | 2,511 | - | 1,593 |
| Appropriation and distribution of retained earnings: | ||||||||
| Legal reserve | - | - | 6,207 | - | (6,207) | - | - | - |
| Reversal of special reserve | - | - | - | (4,607) | 4,607 | - | - | - |
| Cash dividends on ordinary shares | - | - | - | - | (54,498) | - | - | (54,498) |
| Balance at December 31, 2025 | $ 605,536 | 474,527 | 109,078 | 7,592 | 64,843 | (136) | (4,945) | 1,256,495 |
Chairman: WILBER HUANG
(See accompanying notes to financial statements.)
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Abnova (Taiwan) Corporation and Subsidiaries
Consolidated Statements of Cash Flows
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| 2025 | 2024 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit (loss) before tax | $ (2,029) | 73,189 |
| Adjustments: | ||
| Adjustments to reconcile profit (loss) | ||
| Depreciation expenses | 19,424 | 19,913 |
| Amortization expenses | 9,189 | 10,050 |
| Expected credit losses (reversal gains) | 418 | (687) |
| Interest expense | 424 | 118 |
| Interest income | (10,757) | (17,315) |
| Share of associates and joint ventures losses accounted for using equity method | 543 | 205 |
| Losses on liquidation of subsidiaries | 2,837 | - |
| Total adjustments to reconcile profit (loss) | 22,078 | 12,284 |
| Changes in operating assets and liabilities: | ||
| Changes in operating assets: | ||
| Accounts and notes receivable | (7,657) | (2,456) |
| Other receivables | 518 | (166) |
| Inventories | (20,778) | (45,584) |
| Other current assets | 7,082 | 217 |
| Total changes in operating assets | (20,835) | (47,989) |
| Changes in operating liabilities: | ||
| Contract liabilities | 102 | 134 |
| Accounts payable | (4,582) | 4,047 |
| Other payables | (6,408) | (2,208) |
| Other current liabilities | 254 | (384) |
| Other liabilities | (192) | - |
| Total changes in operating liabilities | (10,826) | 1,589 |
| Total changes in operating assets and liabilities | (31,661) | (46,400) |
| Total adjustments | (9,583) | (34,116) |
| Cash inflow generated from (used in) operations | (11,612) | 39,073 |
| Interest received | 11,109 | 17,329 |
| Interest paid | (424) | (118) |
| Income taxes paid | (3,265) | (5,432) |
| Net cash flows from (used in) operating activities | (4,192) | 50,852 |
| Cash flows used in investing activities: | ||
| Acquisition of property, plant and equipment | (3,542) | (6,620) |
| Other receivables | - | 27,597 |
| Acquisition of intangible assets | (2,292) | (1,097) |
| Other financial assets | 39 | (11) |
| Other non-current assets | (423) | (81) |
| Other non-current liabilities | - | (11) |
| Net cash flows generated from (used in) investing activities | (6,218) | 19,777 |
| Cash flows from financing activities: | ||
| Repayment of lease principles | (5,508) | (5,494) |
| Cash dividends paid | (54,498) | (43,598) |
| Net cash flows from financing activities | (60,006) | (49,092) |
| Effect of exchange rate changes on cash and cash equivalents | (297) | 3,493 |
| Net increase (decrease) in cash and cash equivalents | (70,713) | 25,030 |
| Cash and cash equivalents at beginning of period | 448,545 | 423,515 |
| Cash and cash equivalents at end of period | $ 377,832 | 448,545 |
(See accompanying notes to financial statements.)
Chairman: WILBER HUANG
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Independent Auditors' Report
To the Board of Directors of Abnova (Taiwan) Corporation:
Opinion
We have audited the financial statements of Abnova (Taiwan) Corporation (“the Company”), which comprise the balance sheets as of December 31, 2025 and 2024, the statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the financial statements, including a summary of significant accounting policies.
In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.
Basis for Opinion
We conducted our audits in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and auditing standards. Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Parent Company Only Financial Statement section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Key audit matter
Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. The key audit matters we judge that shall be communicated in the audit report are as follows:
- Inventory valuation
Please refer to Note 4(7) “Inventories”; Note 5(1) “Significant accounting assumptions and judgments, and major sources of estimation uncertainty”, and Note 6(4) “Inventories”.
- 23 -
Description of key audit matter:
The major business of the Company is the manufacturing and sales of antibody, protein, test reagents and testing instruments. Inventories are measured at the lower of cost and net realizable value. Due to the longer life cycle of the products, the management considers factors such as product circulation, exposure, preservation and industry information to evaluate the net realizable value of inventories. As the Company has large amount of inventories and a large number of items, and the net realizable value used in the above-mentioned evaluation involves subjective judgment, the evaluation of loss allowance for inventory valuation has been listed as the key audit matter of the year.
Our principal audit procedures included:
The key audit procedures for the above-mentioned key audit matter based on the understanding of the industrial characteristics of the Company include obtaining statistical information on the sales time and sales status of the products on the shelves in each year provided by the management in the subsequent years to evaluate the rationality of the policy used to recognize the inventory valuation loss; understanding the Company's inventory management process, reviewing the annual inventory plan and participating in the annual inventory check to evaluate the effectiveness of the management's inventory control; obtaining the inventory net realizable value calculation sheet, and spot check the correctness of the calculation.
Responsibilities of management and those charged with governance for the financial statements
Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
Those charged with governance (including the Audit Committee) are responsible for overseeing the Company's financial reporting process.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
As part of an audit in accordance with auditing standards, we exercise professional judgment and professional skepticism throughout the audit. We also:
A. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 24 -
B. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
C. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
D. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company's to cease to continue as a going concern.
E. Evaluate the overall presentation, structure and content of the financial reports, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
F. Obtain sufficient and appropriate audit evidence regarding the financial information of the investment in other entities accounted for using the equity method to express an opinion on these financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.
We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.
KPMG
Auditors :
Securities : Financial-Supervisory-Securitie
Competents-Auditing-1080303300
Authority Financial-Supervisory-Securitie
Approved-certified No.
February 25, 2026
Abnova (Taiwan) Corporation
Balance Sheets
December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| Assets | December 31, 2025 | December 31, 2024 | Liabilities and equity | December 31, 2025 | December 31, 2024 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Amount | % | Amount | % | Amount | % | Amount | % | |||
| Current assets: | Current liabilities: | |||||||||
| 1100 | Cash and cash equivalents (Note 6(1)) | $ 376,966 | 28 | 439,796 | 31 | 2130 | Contract liability-current (Note 6(14)) | $ 2,585 | - | 2,483 |
| 1170 | Accounts receivable, net (Note 6(3)) | 50,305 | 4 | 43,066 | 3 | 2170 | Accounts payable | 14,400 | 1 | 18,982 |
| 1200 | Other receivables | 2,384 | - | 3,116 | - | 2200 | Other payables | 25,892 | 2 | 32,300 |
| 1220 | Current tax assets (Note 6(11)) | 6,388 | 1 | 3,687 | 1 | 2280 | Current lease liabilities (Note 6(9)) | 5,212 | - | 5,508 |
| 130X | Inventories (Note 6(4)) | 468,874 | 35 | 451,886 | 32 | 2300 | Other current liabilities | 12,089 | 1 | 5,403 |
| 1479 | Other current assets (Note 8) | 9,675 | 1 | 16,746 | 1 | Total current liabilities | 60,178 | 4 | 64,676 | |
| Total current assets | 914,592 | 69 | 958,297 | 68 | Non-current liabilities: | |||||
| Non-current assets: | 2570 | Deferred tax liabilities (Note 6(11)) | 2,942 | - | 8,006 | |||||
| 1517 | Non-current financial assets at fair value through other comprehensive income (Note 6(2)) | - | - | - | - | 2580 | Non-current lease liabilities (Note 6(9)) | 13,287 | 1 | 18,498 |
| 1550 | Investments accounted for using equity method (Note 6(5)) | 6,772 | 1 | 8,994 | 1 | 2600 | Other non-current liabilities (Note 6(5) and Note 7) | 234 | - | 427 |
| 1600 | Property, plant and equipment (Note 6(6)) | 242,235 | 18 | 252,184 | 18 | Total non-current liabilities | 16,463 | 1 | 26,931 | |
| 1755 | Right-of-use assets (Note 6(7)) | 18,278 | 1 | 23,936 | 2 | Total liabilities | 76,641 | 5 | 91,607 | |
| 1780 | Intangible assets (Note 6(8)) | 59,580 | 4 | 62,687 | 4 | Equity (Note 6(12)) | ||||
| 1840 | Deferred tax assets (Note 6(11)) | 87,684 | 7 | 91,258 | 7 | 3110 | Ordinary share | 605,536 | 45 | 605,536 |
| 1900 | Other non-current assets (Note 6(10) and Note 8) | 3,995 | - | 3,651 | - | 3200 | Capital surplus | 474,527 | 36 | 474,527 |
| Total non-current assets | 418,544 | 31 | 442,710 | 32 | Retained earnings: | |||||
| 3310 | Legal reserve | 109,078 | 8 | 102,871 | ||||||
| 3320 | Special reserve | 7,592 | 1 | 12,199 | ||||||
| 3350 | Unappropriated retained earnings | 64,843 | 5 | 121,859 | ||||||
| 3400 | Other equity interest | (5,081) | - | (7,592) | ||||||
| Total equity | 1,256,495 | 95 | 1,309,400 | |||||||
| Total assets | $ 1,333,136 | 100 | 1,401,007 | 100 | Total liabilities and equity | $ 1,333,136 | 100 | 1,401,007 | 100 |
Chairman: WILBER HUANG
(See accompanying notes to financial statements.)
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Abnova (Taiwan) Corporation
Statements of Comprehensive Income
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| 2025 | 2024 | ||||
|---|---|---|---|---|---|
| Amount | % | Amount | % | ||
| 4000 | Operating revenue (Note 6(14) and Note 7) | $ 351,299 | 100 | 354,700 | 100 |
| 5000 | Operating costs (Note 6(4)) | (195,488) | (56) | (191,998) | (54) |
| 5900 | Net gross profit | 155,811 | 44 | 162,702 | 46 |
| Operating expenses: | |||||
| 6100 | Marketing expenses | (47,828) | (13) | (42,220) | (12) |
| 6200 | Administrative expenses | (43,554) | (13) | (46,212) | (13) |
| 6300 | R&D expenses | (45,561) | (13) | (40,025) | (11) |
| 7055 | Gains on reversal of expected credit (loss) (Note 6(3)) | (418) | - | 687 | - |
| Total operating expenses | (137,361) | (39) | (127,770) | (36) | |
| 6900 | Net operating income | 18,450 | 5 | 34,932 | 10 |
| Non-operating income and expenses (Note 6(16)): | |||||
| 7100 | Interest income | 10,701 | 3 | 16,852 | 5 |
| 7010 | Other income | 19 | - | 44 | - |
| 7020 | Other gains and losses | (26,061) | (7) | 22,017 | 6 |
| 7050 | Finance cost | (424) | - | (118) | - |
| 7060 | Share of associates and joint ventures income accounted for using equity method (Note 6(5)) | (4,733) | (1) | (577) | - |
| Total non-operating income and expenses | (20,498) | (5) | 38,218 | 11 | |
| 7900 | Profit (loss) from continuing operations before tax | (2,048) | - | 73,150 | 21 |
| 7950 | Tax expense (benefit) (Note 6(11)) | (907) | - | 11,543 | 3 |
| 8200 | Profit (loss) | (1,141) | - | 61,607 | 18 |
| Other comprehensive income: | |||||
| 8310 | Components of other comprehensive income that will not be reclassified to profit or loss | ||||
| 8311 | Remeasurements of defined benefit plans (Note 6(10)) | 223 | - | 465 | - |
| 8349 | Less: Income tax related to components of other comprehensive income that will not be reclassified to profit or loss | - | - | - | - |
| Components of other comprehensive income that will not be reclassified to profit or loss | 223 | - | 465 | - | |
| 8360 | Components of other comprehensive income (loss) that may be reclassified to profit or loss | ||||
| 8361 | Exchange differences on translation of foreign financial statements (Note 6(12)) | 2,511 | 1 | 4,607 | 1 |
| 8399 | Less: Income tax related to components of other comprehensive income that may be reclassified to profit or loss | - | - | - | - |
| Components of other comprehensive income (loss) that may be reclassified to profit or loss | 2,511 | 1 | 4,607 | 1 | |
| 8300 | Other comprehensive income, net of tax | 2,734 | 1 | 5,072 | 1 |
| 8500 | Total comprehensive income | $ 1,593 | 1 | 66,679 | 19 |
| Earnings (losses) per share (NT dollars) (Note 6(13)) | |||||
| 9750 | Basic earnings (losses) per share (NT dollars) | $ | (0.02) | 1.02 | |
| 9850 | Diluted earnings (losses) per share (NT dollars) | $ | (0.02) | 1.02 |
(See accompanying notes to financial statements.)
Chairman: WILBER HUANG
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Abnova (Taiwan) Corporation
Statements of Changes in Equity
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| Ordinary shares | Capital surplus | Retained earnings | Other equity interest | Total equity | ||||
|---|---|---|---|---|---|---|---|---|
| Legal reserve | Special reserve | Unappropriated retained earnings | Exchange differences on translation of foreign financial statements | Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income | ||||
| Balance at January 1, 2024 | $ 605,536 | 474,527 | 98,565 | 11,907 | 107,983 | (7,254) | (4,945) | 1,286,319 |
| Profit | - | - | - | - | 61,607 | - | - | 61,607 |
| Other comprehensive income | - | - | - | - | 465 | 4,607 | - | 5,072 |
| Total comprehensive income | - | - | - | - | 62,072 | 4,607 | - | 66,679 |
| Appropriation and distribution of retained earnings: | ||||||||
| Legal reserve | - | - | 4,306 | - | (4,306) | - | - | - |
| Special reserve | - | - | - | 292 | (292) | - | - | - |
| Cash dividends on ordinary shares | - | - | - | - | (43,598) | - | - | (43,598) |
| Balance at December 31, 2024 | 605,536 | 474,527 | 102,871 | 12,199 | 121,859 | (2,647) | (4,945) | 1,309,400 |
| Loss | - | - | - | - | (1,141) | - | - | (1,141) |
| Other comprehensive income | - | - | - | - | 223 | 2,511 | - | 2,734 |
| Total comprehensive income | - | - | - | - | (918) | 2,511 | - | 1,593 |
| Appropriation and distribution of retained earnings: | ||||||||
| Legal reserve | - | - | 6,207 | - | (6,207) | - | - | - |
| Reversal of special reserve | - | - | - | (4,607) | 4,607 | - | - | - |
| Cash dividends on ordinary shares | - | - | - | - | (54,498) | - | - | (54,498) |
| Balance at December 31, 2025 | $ 605,536 | 474,527 | 109,078 | 7,592 | 64,843 | (136) | (4,945) | 1,256,495 |
Chairman: WILBER HUANG
(See accompanying notes to financial statements.)
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Abnova (Taiwan) Corporation
Statements of Cash Flows
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars)
| 2025 | 2024 | |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit (loss) before tax | $ (2,048) | 73,150 |
| Adjustments: | ||
| Adjustments to reconcile profit (loss) | ||
| Depreciation expenses | 19,401 | 19,825 |
| Amortization expenses | 9,189 | 10,050 |
| Expected credit losses (reversal gains) | 418 | (687) |
| Interest expense | 424 | 118 |
| Interest income | (10,701) | (16,852) |
| Share of subsidiaries, associates and joint ventures losses accounted for using equity method | 4,733 | 577 |
| Total adjustments to reconcile profit (loss) | 23,464 | 13,031 |
| Changes in operating assets and liabilities: | ||
| Changes in operating assets: | ||
| Accounts receivable | (7,657) | (2,530) |
| Other receivables | 378 | 93 |
| Inventories | (20,778) | (45,584) |
| Other current assets | 7,082 | (74) |
| Total changes in operating assets | (20,975) | (48,095) |
| Changes in operating liabilities: | ||
| Contract liabilities | 102 | 134 |
| Accounts payable | (4,582) | 4,047 |
| Other payables | (6,408) | 670 |
| Other current liabilities | 6,686 | (384) |
| Other liabilities | (192) | - |
| Total changes in operating liabilities | (4,394) | 4,467 |
| Total changes in operating assets and liabilities | (25,369) | (43,628) |
| Total adjustments | (1,905) | (30,597) |
| Cash inflow generated from (used in) operations | (3,953) | 42,553 |
| Interest received | 11,055 | 16,866 |
| Interest paid | (424) | (118) |
| Income taxes paid | (3,284) | (5,389) |
| Net cash flows from operating activities | 3,394 | 53,912 |
| Cash flows used in investing activities: | ||
| Cash refund from capital reduction of investees accounted for using equity method | - | 82,467 |
| Acquisition of property, plant and equipment | (3,542) | (6,620) |
| Acquisition of intangible assets | (2,292) | (1,097) |
| Other financial assets | 39 | (11) |
| Other non-current assets | (423) | (81) |
| Other non-current liabilities | - | (11) |
| Net cash flows (outflows) used in investing activities | (6,218) | 74,647 |
| Cash flows from financing activities: | ||
| Repayment of lease principles | (5,508) | (5,494) |
| Cash dividends paid | (54,498) | (43,598) |
| Net cash flows from financing activities | (60,006) | (49,092) |
| Net increase (decrease) in cash and cash equivalents | (62,830) | 79,467 |
| Cash and cash equivalents at beginning of period | 439,796 | 360,329 |
| Cash and cash equivalents at end of period | $ 376,966 | 439,796 |
(See accompanying notes to financial statements.)
Chairman: WILBER HUANG
Manager: JIH PEI JU
Accounting supervisor: CHANG YA PING
Appendix 4
Abnova (Taiwan) Corporation 2025 Profit Distribution Statement
Unit: NTD
| Items | Amount | |
|---|---|---|
| Beginning retained earnings | 65,760,459 | |
| Add: 2025 net loss after tax | (1,141,279) | |
| Add: Remeasurements of the net defined benefit plan recognized in retained earnings (Note1) | 223,096 | |
| Net loss after tax of the current period plus the amount of items other than net loss after tax of the current period included in the unappropriated retained earnings of the current year | (918,183) | |
| Add: Reversal of special reserve - Deduction from Other Equity | 2,511,476 | |
| Distributable net profit | 67,353,752 | |
| Distributable items | ||
| Dividend to shareholders- Cash (NTD 0.112/share) | (6,782,003) | |
| Unappropriated retained earnings | 60,571,749 |
Note 1: Other comprehensive profits and losses are recognized according to the pension actuarial report.
Chairperson: Wilber Huang General Manager: Jih Pei Ju Accounting Officer: Chang Ya Ping
- 30 -
Appendix 5
Abnova (Taiwan) Corporation
Comparison table between the revision and the original of "Procedures for Acquisition or Disposal of Assets"
| Revision | Original | Explanation |
|---|---|---|
| Article 14: Procedures for public disclosure of information | Article 14: Procedures for public disclosure of information | Amended to comply with the Financial Supervisory Commission's Letter No. 1140383333, dated July 24, 2025. |
| 1. Items to be announced and declared, and the standards for announcement and declaration (i)~ (iii) (Omitted) | 1. Items to be announced and declared, and the standards for announcement and declaration (i)~ (iii) (Omitted) | |
| (iv) Where the assets acquired or disposed of are equipment for operational use or right-of-use assets thereof, the counterparty is not a related party, and the transaction amount meets any of the following thresholds: | (iv) Where the assets acquired or disposed of are equipment for operational use or right-of-use assets thereof, the counterparty is not a related party, and the transaction amount meets any of the following thresholds: | |
| A. For a public company with paid-in capital of less than NT$ 10 billion, the transaction amount reaches NT$ 500,000,000 or more. | A. For a public company with paid-in capital of less than NT$ 10 billion, the transaction amount reaches NT$ 500,000,000 or more. | |
| B. For a public company with paid-in capital of NT$ 10 billion or more but less than NT$50 billion, the transaction amount reaches NT$ 1 billion or more. | B. For a public company with paid-in capital of NT$ 10 billion or more, the transaction amount reaches NT$ 1 billion or more. | |
| C. For a public company with paid-in capital of NT$50 billion or more, the transaction amount exceeds 5% of the Company's paid-in capital. | (v) Where a public company engaged in construction business acquires or disposes of real property for construction use or right-of-use assets thereof, the counterparty is not a related party, and the transaction amount reaches NT$ 500,000,000 or more; provided that where the paid-in capital reaches NT$10 billion or more, and the Company disposes of self-constructed completed real property projects to a non-related party, the transaction amount shall reach NT$1 billion or more. | |
| (v) Where a public company engaged in construction business acquires or disposes of real property for construction use or right-of-use assets thereof, the counterparty is not a related party, and the transaction amount reaches NT$ 500,000,000 or more; provided that where the paid-in capital reaches NT$10 billion or more, and the Company disposes of self-constructed completed real property projects to a non-related party, the transaction amount shall reach NT$1 billion or more. | (vi) Where the Company acquires real property through arrangements such as build-on-own-land, build-on-leased-land, joint construction with allocation of units, joint construction with profit-sharing, or joint construction for sale, the counterparty is not a related party, and the Company's estimated transaction amount reaches |
| Revision | Original | Explanation |
|---|---|---|
| construction with profit-sharing, or joint construction for sale, the counterparty is not a related party, and the Company’s estimated transaction amount reaches NT$ 500,000,000 or more. |
(vii) Where a public company with paid-in capital of NT$50 billion or more trades government bonds, corporate bonds, or general financial bonds not involving equity (excluding subordinated bonds) on a securities exchange or at a place of business of a securities firm, and such transactions do not fall under the provision of Subparagraph 8, and the counterparty is not a related party, the transaction amount reaches 5% or more of the Company’s paid-in capital.
(viii) For asset transactions other than those specified in the preceding seven subparagraphs, disposal of claims by financial institutions, or investments in Mainland China, where the transaction amount reaches 20% or more of the Company’s paid-in capital or NT$ 300,000,000 million or more; provided, however, that the following shall not apply:
A. Trading of domestic government bonds or foreign government bonds with a credit rating not lower than the sovereign rating of Taiwan.
B. For entities specializing in investment, trading of securities conducted on domestic or foreign securities exchanges or at places of business of securities firms, or subscription in the domestic primary market of foreign government bonds or publicly offered corporate bonds and general financial bonds not involving equity (excluding subordinated bonds), or subscription or redemption of securities investment trust funds or futures trust funds, or subscription or redemption of exchange-traded notes (ETNs), or securities subscribed by securities firms as required for underwriting business or as recommending securities firms for | NT$ 500,000,000 or more.
(vii) For asset transactions other than those specified in the preceding six subparagraphs, disposal of claims by financial institutions, or investments in Mainland China, where the transaction amount reaches 20% or more of the Company’s paid-in capital or NT$ 300,000,000 million or more; provided, however, that the following shall not apply:
A. Trading of domestic government bonds or foreign government bonds with a credit rating not lower than the sovereign rating of Taiwan.
B. For entities specializing in investment, trading of securities conducted on domestic or foreign securities exchanges or at places of business of securities firms, or subscription in the domestic primary market of foreign government bonds or publicly offered corporate bonds and general financial bonds not involving equity (excluding subordinated bonds), or subscription or redemption of securities investment trust funds or futures trust funds, or subscription or redemption of exchange-traded notes (ETNs), or securities subscribed by securities firms as required for underwriting business or as recommending securities firms for emerging stock companies in accordance with the regulations of the Taipei Exchange.
C. Trading of bonds with repurchase or reverse repurchase conditions, or subscription or redemption of money market funds issued by domestic securities investment trust enterprises.
(viii) The calculation of the transaction amount referred to in the preceding paragraph shall be as follows. The term “within one year” as used in this Paragraph shall be calculated retrospectively from the date of occurrence of the current transaction. Any portion that has already been | |
- 32 -
| Revision | Original | Explanation |
|---|---|---|
| emerging stock companies in accordance with the regulations of the Taipei Exchange. | ||
| C. Trading of bonds with repurchase or reverse repurchase conditions, or subscription or redemption of money market funds issued by domestic securities investment trust enterprises. | ||
| (ix) The calculation of the transaction amount referred to in the preceding paragraph shall be as follows. The term “within one year” as used in this Paragraph shall be calculated retrospectively from the date of occurrence of the current transaction. Any portion that has already been publicly announced in accordance with these Procedures need not be included again: | ||
| A. The amount of each individual transaction. | ||
| B. The cumulative amount of transactions involving the acquisition or disposal of assets of the same nature with the same counterparty within one year. | ||
| C. The cumulative amount of acquisitions or disposals (calculated separately for acquisitions and disposals) of real property or right-of-use assets thereof under the same development project within one year. | ||
| D. The cumulative amount of acquisitions or disposals (calculated separately for acquisitions and disposals) of the same securities within one year. | publicly announced in accordance with these Procedures need not be included again: | |
| A. The amount of each individual transaction. | ||
| B. The cumulative amount of transactions involving the acquisition or disposal of assets of the same nature with the same counterparty within one year. | ||
| C. The cumulative amount of acquisitions or disposals (calculated separately for acquisitions and disposals) of real property or right-of-use assets thereof under the same development project within one year. | ||
| D. The cumulative amount of acquisitions or disposals (calculated separately for acquisitions and disposals) of the same securities within one year. | ||
| 2.~3. (Omitted) | ||
| Article 18: Additional provisions | ||
| 1. Any other matter not set forth in the Procedures shall be handled in accordance with related laws and regulations. | ||
| 2. The Procedures were established on May 27, 2004. | ||
| 3. The first amendment was made on June 30, 2008. | ||
| 4. The second amendment was made on June 15, 2012. | ||
| 5. The third amendment was made on June 23, 2014. | Article 18: Additional provisions | |
| 1. Any other matter not set forth in the Procedures shall be handled in accordance with related laws and regulations. | ||
| 2. The Procedures were established on May 27, 2004. | ||
| 3. The first amendment was made on June 30, 2008. | ||
| 4. The second amendment was made on June 15, 2012. | ||
| 5. The third amendment was made on June 23, 2014. | Added revision date. |
| Revision | Original | Explanation |
|---|---|---|
| 6. The fourth amendment was made on June 23, 2015. | 6. The fourth amendment was made on June 23, 2015. | |
| 7. The fifth amendment was made on June 23, 2017. | 7. The fifth amendment was made on June 23, 2017. | |
| 8. The sixth amendment was made on June 26, 2019. | 8. The sixth amendment was made on June 26, 2019. | |
| 9. The seventh amendment was made on May 31, 2022. | 9. The seventh amendment was made on May 31, 2022. | |
| 10. The eighth amendment was made on May 29, 2026. |
- 34 -